| abstract |
Genes, SNP markers and haplotypes of susceptibility or predisposition to CHD such as AMI are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for AMI using polymorphisms in the AMI risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of AMI and CHD. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of CHD and AMI. |